WUMC-Cancer and Leukemia Group B

WUMC-癌症和白血病 B 组

基本信息

批准号：
7258873
负责人：
NANCY L BARTLETT
金额：
$ 33.44万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
起止时间：
1998-05-08 至 2009-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7258873
关键词：
12p 18q 5&apos Untranslated Regions ABCB1 gene Academic Medical Centers Accountability Acetates Acids Acute Myelocytic Leukemia Adenocarcinoma Adjuvant Adjuvant Study Adopted Adrenal Glands Adult Advanced Malignant Neoplasm Adverse Drug Experience Reporting System Allogenic Amendment American College of Radiology Imaging Network American College of Surgeons Oncology Group Aminocamptothecin Androgen Antagonists Androgen Receptor Androgens Animals Antibodies Antineoplastic Agents Apoptotic Appointment Area Arsenic Trioxide Authorship Award Awareness Back Barrett Esophagus Basic Science Beds Bexarotene Bibliography Biliary Tract Neoplasm Bioinformatics Biological Markers Biopsy Biostatistics Core Blood Cells Body of uterus Bone Density Bone Marrow Bone Marrow Transplantation Breast Budgets Cachexia Cancer Center Cancer Center Support Grant Cancer Control Cancer Patient Cancer Research Project Cancer Therapy Evaluation Program Cancer and Leukemia Group B Candidate Disease Gene Capital Carboplatin Carboplatin/Etoposide/Exisulind Cardiovascular system Caring Categories Cell Cycle Cell Proliferation Cells Cellular biology Chairperson Charge Chest Cholangiocarcinoma Cisplatin Cisplatin/Cytarabine/Etoposide/Methylprednisolone Classification Clinic Clinical Clinical Pharmacists Clinical Protocols Clinical Research Clinical Research Associate Clinical Trials Closure Code Collaborations Colon Colon Carcinoma Colon, Rectum Color Colorectal Colorectal Cancer Commit Committee Members Committee Membership Communication Communities Condition Conflict (Psychology)Conflict of Interest Conformal Radiotherapy Consent Consultations Core Facility Correlation Studies Correlative Study Cyclophosphamide/Doxorubicin/Etoposide/Prednisone/Vincristine Cytogenetics DNA Sequence Daily Data Data Analyses Data Collection Data Quality Databases Development Developmental Biology Developmental Therapeutics Program Diagnosis Diarrhea Diffuse Lymphoma Discipline Disease Disorder by Site Docetaxel/Estramustine Docetaxel/Gemcitabine Docetaxel/Irinotecan Doctor of Medicine Doctor of Philosophy Dose Doxorubicin/Gemcitabine Doxorubicin/Topotecan Doxorubicin/Vinblastine Drug Kinetics Eastern Cooperative Oncology Group Economics Education Educational workshop Elderly Eligibility Determination Enrollment Ensure Equipment and supply inventories Etoposide Evaluation Excision Extensive Stage Faculty Familiarity Fellowship Film Fluorouracil Fluorouracil/Interferon Alfa Flutamide Focus Groups Follow-Up Studies Fostering Functional Imaging Funding Future GG918 Gastrointestinal Lymphoma Gemcitabine/Vinorelbine Gene Mutation Genes Genetic Genetic Polymorphism Genitourinary system Genomics Genotype Genus Cola Goals Grant Group Meetings Growth Growth Factor Guidelines Gynecologic Oncology Group Head Health Health behavior Hematologic Neoplasms Hematology Hepatobiliary Hepatocyte Growth Factor Hereditary Malignant Neoplasm Hodgkin Disease Hormonal Hospitals Hour Housing Human Human Resources Hydrocortisone Ifosfamide Ifosfamide/Paclitaxel Ifosfamide/Vinorelbine Illinois Image Imaging Techniques Imatinib mesylate Incidence Individual Industry Infusion procedures Institutes Institution Interleukin-2 Investigation Investigational Drugs Irinotecan/UCN-01 Ketoconazole Kidney LY 335979 Label Laboratories Lead Leadership Left Legal Length Leucovorin Levamisole Life Ligands Liposomal Doxorubicin Liposomes Localized Lung Lymphatic Irradiation Lymphoma Magnetic Resonance Imaging Mails Maintenance Malignant Neoplasms Malignant mesothelioma Malignant neoplasm of esophagus Malignant neoplasm of lung Malignant neoplasm of pancreas Malignant neoplasm of prostate Mammary Neoplasms Manuscripts Medical Medical Oncologist Medical Oncology Medical center Mesenchymal Stem Cells Mesothelioma Methods Micrometastasis Minority Mission Missouri Mitoxantrone Modality Modeling Modification Molecular Monitor Monoclonal Antibodies Mutation N(delta)-acetylornithine, -isomer N-dodecanoylglutamic acid, -isomer, sodium salt NCI-Designated Cancer Center Names Navelbine ditartrate Neoadjuvant Therapy Neutropenia Newly Diagnosed Nodal Non-Hodgkin&apos s Lymphoma Non-Small-Cell Lung Carcinoma Normal tissue morphology Numbers Nurses Oncologist Oncology Group Online Systems Ontology Operative Surgical Procedures Oral Oropharyngeal Outcome Outcomes Research Outpatients P-Glycoprotein P-Glycoproteins Palliative Care Pancreas Participant Pathogenesis Pathology Patient Care Patient Monitoring Patients Peer Review Perception Performance Peripheral Pharmaceutical Preparations Pharmacists Pharmacodynamics Pharmacogenetics Pharmacogenomics Pharmacologic Substance Pharmacology Pharmacy facility Phase Phase I Clinical Trials Phase I/II Trial Phase II Clinical Trials Phase III Clinical Trials Physicians Pilot Projects Placebos Plastic Surgical Procedures Point Mutation Policies Polyribosomes Positioning Attribute Positron-Emission Tomography Preclinical Drug Development Preparation Principal Investigator Printing Procedures Process Prognostic Marker Program Research Project Grants Progressive Disease Prostate Prostate Cancer therapy Prostatic Neoplasms Protein Tyrosine Kinase Protocol Compliance Protocols documentation Psychosocial Assessment and Care Publications Published Comment Publishing Quality of life RNA Sequences Radiation Radiation Oncologist Radiation Oncology Radiation Therapist Radiation Therapy Oncology Group Radiation therapy Radiology Specialty Radiosurgery Randomized Rate Receptor Protein-Tyrosine Kinases Recombinants Recommendation Records Recruitment Activity Rectal Cancer Recurrence Refractory Registries Relapse Reporting Research Research Design Research Ethics Committees Research Infrastructure Research Personnel Research Project Grants Resected Resources Retinoids Reverse Transcriptase Polymerase Chain Reaction Review Committee Risk Roche brand of trastuzumab Role Running SDZ-PSC-833 SGN-30 SU11248 Safety Salvage Therapy Sampling Schedule Science Secure Seeds Series Serious Adverse Event Serum Markers Services Site Solid Solid Neoplasm Source Southwest Oncology Group Specific qualifier value Specimen Speed Staging Stem Cell Research Stem cell transplant Stem cells Stomach Surgeon Surgical Pathology Surveys System TNFRSF8 gene Tamoxifen Tandem Repeat Sequences Technology Telefacsimile Telephone Temperature Testing Therapeutic Therapeutic Studies Therapy Clinical Trials Thermometers Thoracic Oncology Thoracic Surgeon Thoracic Surgical Procedures Time Tissue Procurements Title Topoisomerase Inhibitors Topotecan Toxic effect Trainers Training Training Translating Translational Research Transplantation Travel Treatment Protocols Tumor Burden Tumor Suppressor Genes Tyrosine Tyrosine Kinase Inhibitor Umbilical Cord Blood United States United States Food and Drug Administration United States National Institutes of Health Universities Unresectable Urology Ursidae Family Valspodar Veterans Visit Washington Week Withdrawal Woman Work Workload Y 90 Ibritumomab Tiuxetan ZD1839 (IRESSA)abstracting alpha-difluoromethyl-DOPA, -isomer alpha-methylornithine dihydrochloride, -isomer analog androgen independent prostate cancer anticancer research base bevacizumab bleomycin/dacarbazine/doxorubicin/vinblastine protocol cancer care cancer cell cancer genetics cancer imaging cancer prevention cancer statistics cancer surgery cancer type celecoxib chemosensitizing agent chemotherapy clinical conference clinically relevant cognitive function cohort concept data management database design day docetaxel doxorubicin/etoposide/vinblastine protocol embryonic stem cell experience expiration falls flavopiridol follow-up follower of religion Jewish gastrointestinal gemcitabine hormone refractory prostate cancer hormone therapy human prostaglandin D2 receptor human study human subject improved inhibitor/antagonist innovation interest irinotecan leukemia leukemia/lymphoma lung small cell carcinoma malignant breast neoplasm medical specialties melanoma member men metropolitan molecular imaging molecular oncology multidisciplinary neuropsychiatry novel older patient oncology oxaliplatin pilot trial prescription document prescription procedure prevent probation prognostic programs prospective quality assurance receptor research study respiratory response rituximab rosiglitazone small molecule statistical center symposium symptom management translational study trend tumor tumor immunology uptake

项目摘要

DESCRIPTION (adapted from the applicant's abstract): Washington University has been a CALGB main member institution since 1986. Over the last five years, the cancer research program at the Washington University Medical Center (WUMC) has experienced tremendous growth. Barnes-Jewish Hospital, the largest hospital in St. Louis, diagnoses more than 5,400 patients a year with cancer and remains the major referral center for southeast Missouri and southern Illinois. The Siteman Cancer Center (SCC) at WUMC received NCI-designated Cancer Center status in August 2001. The infrastructure developed by the SCC to compete successfully for the NCI Cancer Center Support Grant has significantly enhanced our ability to carry out all aspects of clinical cancer research, including cooperative group trials. Our recent efforts to expand institutional research studies will significantly enhance our ability to contribute concepts to CALGB during the next grant cycle, specifically in the areas of Hematologic malignancies, thoracic oncology, and pharmacogenomics. Between 1998 and 2002, 16 Washington University physicians and research assistants served on 36 different CALGB scientific and administrative committees. WUMC investigators chaired 12 CALGB studies, including Phase II studies in non-Hodgkin's lymphoma, Hodgkin's lymphoma, prostate cancer, mesothelioma, and several pharmacokinetic and pharmacogenomic correlative science studies. Six additional studies are in the final stages of development. Accrual to CALGB trials has continued to increase during this grant period, with an average of 183 patients per year registered to therapeutic and non-therapeutic trials from 1998 to 2001. Accrual to therapeutic trials increased from 61 patients in 1998 to 105 in 2001. Based on registrations to date, projected accrual to CALGB trials for 2002 is estimated to be 312, with 136 to therapeutic studies. Plans for the next grant cycle include 1) continued involvement by all current WUMC investigators, 2) increased participation by our Phase I investigators to facilitate development of Phase II studies within CALGB, 3) involvement of at least five additional WUMC investigators in CALGB activities including faculty interested in GU oncology, quality of life, stem cell transplant and leukemia, leukemia correlative sciences, and radiation oncology, and 5) continued efforts to increase accruals, particularly minority accruals, to CALGB trials.

描述（改编自申请人的摘要）：华盛顿大学自 1986 年以来一直是 CALGB 主要成员机构。在过去五年中，华盛顿大学医学中心 (WUMC) 的癌症研究项目经历了巨大的发展。巴恩斯犹太医院是圣路易斯最大的医院，每年诊断出 5,400 多名癌症患者，并且仍然是密苏里州东南部和伊利诺伊州南部的主要转诊中心。 WUMC 的斯特曼癌症中心 (SCC) 于 2001 年 8 月获得 NCI 指定癌症中心地位。SCC 为成功竞争 NCI 癌症中心支持拨款而开发的基础设施显着增强了我们开展临床癌症研究各个方面的能力，包括合作小组试验。我们最近扩大机构研究的努力将显着增强我们在下一个资助周期内为 CALGB 贡献概念的能力，特别是在血液恶性肿瘤、胸部肿瘤学和药物基因组学领域。 1998 年至 2002 年间，16 名华盛顿大学医生和研究助理在 36 个不同的 CALGB 科学和管理委员会任职。 WUMC 研究人员主持了 12 项 CALGB 研究，包括非霍奇金淋巴瘤、霍奇金淋巴瘤、前列腺癌、间皮瘤的 II 期研究，以及多项药代动力学和药物基因组相关科学研究。另外六项研究正处于开发的最后阶段。在此资助期间，CALGB 试验的应计人数持续增加，从 1998 年至 2001 年，平均每年有 183 名患者注册参加治疗性和非治疗性试验。治疗性试验的应计人数从 1998 年的 61 名患者增加到 2001 年的 105 名患者。就迄今为止的登记而言，2002 年 CALGB 试验的预计应计人数估计为 312 名，其中136 治疗研究。下一个拨款周期的计划包括 1) 所有现有 WUMC 研究人员继续参与，2) 我们的 I 期研究人员增加参与，以促进 CALGB 内 II 期研究的开展，3) 至少五名额外的 WUMC 研究人员参与 CALGB 活动，包括对 GU 肿瘤学、生活质量、干细胞移植和白血病、白血病相关科学和放射肿瘤学感兴趣的教师，以及 5) 继续努力增加应计费用，特别是少数群体应计费用，以 CALGB 试验。